OrbiMed’s Nektar Therapeutics NKTR Stock Holding History

OrbiMed’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-34,333	Closed	-$296K	–	137
2023 Q2	$296K	Sell	34,333 -2,000	-6%	-$21.3K	0.01%	126
2023 Q1	$383K	Buy	+36,333	New	+$1.1M	0.01%	123

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OrbiMed's NKTR Position: Q1 2026 in Review

OrbiMed opened a new position in Nektar Therapeutics (NKTR) in Q1 2026: 275,000 shares worth $19.8M. The stake represents 0.39% of the portfolio and ranks #58 among its holdings. This is a return to the name: OrbiMed previously reported a position in NKTR as recently as Q1 2023.

OrbiMed first reported a position in NKTR in Q1 2023 and has held it in 2 quarters since. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

OrbiMed held 275,000 shares of Nektar Therapeutics worth $19.8M as of Q1 2026.
Nektar Therapeutics was a new OrbiMed position in Q1 2026.
Nektar Therapeutics made up 0.39% of OrbiMed's portfolio in Q1 2026, its #58 holding.
OrbiMed first reported a position in Nektar Therapeutics in Q1 2023 and has held it in 2 quarters since.
215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.